Abstract
This Viewpoint discusses the potential that newer antiobesity medications can provide for greater weight loss efficacy with an acceptable safety profile, including those with novel “twincretin” mechanisms of action.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
